ATP-Sensing Receptor P2RX4 Emerges as a Molecular Window Into Triple-Negative Breast Cancer’s Immune Landscape

Triple-negative breast cancer has long been the most stubborn subtype of breast malignancy, lacking the estrogen receptor, progesterone receptor, and HER2 amplification that give clinicians clear therapeutic handles in other forms of the disease. What it does have, in abundance, is a notoriously heterogeneous and immunosuppressive tumor microenvironment, a dense and dynamic ecosystem of malignant cells, immune infiltrates, fibroblasts, and signaling molecules that shields the tumor from attack and resists immunotherapy. A new multi-omics study published in BMC Medical Imaging by Yi Fei Meng, Ling Yan Zhang, and colleagues turns its attention to a comparatively underexplored player in that ecosystem: P2RX4, an ATP-gated ion channel receptor with well-documented links to inflammation, whose cell-specific expression patterns and imaging correlates in triple-negative breast cancer had remained poorly mapped until now.

The receptor at the center of the investigation belongs to the P2X family of purinergic receptors, seven related proteins that open in response to extracellular adenosine triphosphate and permit the flow of cations such as calcium and sodium across the cell membrane. Because ATP is released in large quantities by dying and stressed cells, including tumor cells subjected to hypoxia and rapid proliferation, purinergic signaling occupies a strategic position at the interface between tumor metabolism and immune regulation. The P2RX7 receptor, a close relative of P2RX4, has been extensively studied for its role in inflammasome activation and macrophage function, but P2RX4 itself has received far less attention in the context of solid tumors, and almost none in the specific setting of triple-negative breast cancer.

To interrogate P2RX4’s role, the research team assembled a genuinely multi-scale evidence base rather than relying on any single data type. They drew on single-cell RNA sequencing datasets from the Gene Expression Omnibus to resolve which cell types within triple-negative breast tumors actually express the receptor, bulk transcriptomic data from the TCGA-BRCA cohort of the Cancer Genome Atlas to quantify associations between P2RX4 expression and microenvironmental signatures across hundreds of tumors, and the METABRIC cohort for independent cross-cohort validation. On the imaging side, they incorporated dynamic contrast-enhanced MRI data from the Cancer Imaging Archive, extracting radiomic features from a three-millimeter peritumoral shell surrounding the gross tumor volume in a small number of matched cases.

The single-cell analysis produced one of the study’s most consequential findings: within the analyzed triple-negative breast cancer samples, P2RX4 expression was predominantly enriched in epithelial and tumor cells rather than in the immune or stromal compartments. This localization matters because it reframes the receptor not simply as a marker of infiltrating inflammatory cells but as a feature of the malignant cells themselves, positioned to sense ATP released within the tumor core and potentially to participate in the signaling conversations that shape the surrounding microenvironment. The authors used uniform manifold approximation and projection, a standard dimensionality-reduction technique for visualizing single-cell data, to place P2RX4-expressing cells within the broader cellular architecture of the tumors.

Across the bulk transcriptomic analyses, a consistent pattern emerged linking P2RX4 to two hallmarks of an immunosuppressive, metabolically stressed tumor: CD163 expression and hypoxia-related transcriptional features. CD163 encodes a scavenger receptor characteristic of M2-polarized tumor-associated macrophages, the anti-inflammatory wing of the macrophage lineage that is widely associated with tumor progression, immune evasion, and poor response to checkpoint blockade in many cancer types. A positive association between a tumor-cell-expressed ATP receptor and a macrophage marker of this kind suggests a plausible biological axis, one in which purinergic signaling from malignant cells could contribute to recruiting or polarizing the very macrophages that help the tumor hide. The authors were careful to note that the correlation magnitudes were modest, a caveat that reflects the reality of bulk tissue data, which averages signals across many cell types and dilutes cell-specific biology.

The study also compared P2RX4 with its better-known sibling P2RX7 and found that the two receptors displayed different correlation patterns with selected microenvironment-related markers, an observation that argues against treating the P2X family as a monolithic block and supports the idea that each paralog carries distinct information about the tumor ecosystem. In the analyzed triple-negative breast cancer cohort, P2RX4 expression was negatively correlated with VIM, which encodes vimentin, a mesenchymal cytoskeletal protein, and positively correlated with CDH1, which encodes E-cadherin, an epithelial adhesion molecule. Because vimentin gain and E-cadherin loss are classic molecular accompaniments of epithelial-mesenchymal transition, the direction of these correlations might tempt observers to infer an anti-EMT role for the receptor, but the authors explicitly cautioned that such associations do not establish any causal effect on EMT or stromal remodeling. Correlation in bulk transcriptomics, they emphasized, is a hypothesis generator, not a mechanism.

Survival analyses added further nuance and a healthy dose of statistical humility. In the pan-breast-cancer cohort, exploratory analysis suggested that high P2RX4 expression was associated with favorable overall survival, an intriguing result given the receptor’s links to immunosuppressive macrophage signatures. Yet when the analysis was restricted to the triple-negative subgroup, the association did not hold, and the authors reported that the finding was sensitive to the data-driven expression cutpoint used to define high versus low expression. This sensitivity analysis is exactly the kind of transparency that strengthens confidence in a study’s conclusions: rather than presenting a single optimistic survival curve, the team acknowledged that where one draws the threshold in a continuous biomarker distribution can materially change the result, particularly in cohorts as molecularly diverse as unselected breast cancer.

The most visually striking and, by the authors’ own framing, the most preliminary component of the work involved magnetic resonance imaging. Radiomics, the high-throughput extraction of quantitative image features such as gray level co-occurrence matrix texture statistics, gray level run length and size zone matrices, and neighboring gray tone difference measures, has been proposed as a way to read out microscopic tumor biology from macroscopic scans. Because the tumor microenvironment extends beyond the visible tumor margin, the team focused on the peritumoral habitat, a three-millimeter shell of tissue immediately surrounding the gross tumor volume, reasoning that molecular features of the immune microenvironment might leave detectable fingerprints in the texture and heterogeneity of contrast enhancement in this zone. Feature selection followed the standardization conventions of the Image Biomarker Standardization Initiative, and reproducibility was assessed using intraclass correlation coefficients, with principal component analysis used to condense the high-dimensional feature space.

The imaging results, however, were deliberately framed as descriptive and hypothesis-generating. Only four matched MRI cases were analyzed, a sample far too small to establish any imaging-molecular association or to validate a radiomic biomarker, and the authors said so plainly. This candor is worth emphasizing because radiomics has acquired a reputation in some quarters for overclaiming, with models built on small cohorts that fail external validation. By presenting the peritumoral observations as a proof of concept rather than a validated finding, the study models a more disciplined approach: the molecular associations, which rest on large public cohorts, stand on firmer ground, while the imaging correlates are offered as a roadmap for what a properly powered future study should test.

Taken together, the work sketches a coherent research program rather than a finished clinical tool. P2RX4, expressed predominantly by tumor cells in triple-negative breast cancer, tracks with CD163-positive macrophage signatures and hypoxic transcriptional programs, and its expression pattern differs from that of P2RX7, while exploratory peritumoral MRI features hint that such biology might eventually be readable non-invasively. The next steps are clear from the study’s own limitations: larger imaging cohorts with matched molecular data, mechanistic experiments to test whether tumor-cell P2RX4 signaling genuinely shapes macrophage polarization, and validation of survival associations in independent triple-negative-specific cohorts. For a disease that accounts for a disproportionate share of breast cancer mortality and remains the subtype where immunotherapy has delivered the least, even a carefully hedged new molecular lead is worth the field’s attention, and this study provides one with unusual methodological restraint.

Subject of Research: P2RX4-associated immune microenvironment features and peritumoral radiomic phenotypes in triple-negative breast cancer

Article Title: Multi-omics characterization of P2RX4-associated immune microenvironment features and proof-of-concept observations of peritumoral radiomic phenotypes in TNBC

Article References: Meng, Y. F., Zhu, Y. Q., Zhang, Y., Wang, Y. Q., Li, M. F., & Zhang, L. Y. (2026). Multi-omics characterization of P2RX4-associated immune microenvironment features and proof-of-concept observations of peritumoral radiomic phenotypes in TNBC. BMC Medical Imaging. https://doi.org/10.1186/s12880-026-02857-4

Image Credits: AI Generated

DOI: 10.1186/s12880-026-02857-4

Keywords: triple-negative breast cancer, P2RX4, purinergic signaling, tumor microenvironment, tumor-associated macrophages, CD163, hypoxia, single-cell RNA sequencing, radiomics, DCE-MRI, multi-omics, peritumoral region